Could a cancer drug quiet overactive adrenal hormones? a new study investigates.
NCT ID NCT07680205
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This pilot study looks at how belzutifan, a drug already used for some tumors, changes the production of adrenaline-like hormones in people with pheochromocytoma and paraganglioma (PPGL). Over 5 days, researchers measure key substances in the hormone-making process to see if belzutifan can lower excess hormone levels. The study involves 12 adults with confirmed PPGL and aims to understand the drug's effect on hormone metabolism.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Belzutifan
- What this could lead to
- If successful, this could reveal how belzutifan alters hormone production in these rare tumors, potentially guiding future treatments.
- What could go wrong
- This is a very small, early pilot study with only 12 participants and a short 5-day treatment period, so results may not apply broadly or lead directly to new therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHEOCHROMOCYTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cambridge University Hospitals NHS Foundation Trust
RECRUITINGCambridge, Cambridgeshire, CB2 0QQ, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a nudge in your chart unlock Life-Saving genetic clues?
- Can a radioactive 'Smart Bomb' take down resistant childhood cancers?
- Can a radioated molecule shrink untreatable neuroblastoma?
- New drug aims to shrink rare adrenal tumors
- Could a daily pill tame rare cancers in teens? new trial investigates
- Could a smartphone replace clinic visits for rare tumor survivors?